Drug Delivery News and Research RSS Feed - Drug Delivery News and Research

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.
Existing anti-stroke drug can be effective in treating middle-ear infections

Existing anti-stroke drug can be effective in treating middle-ear infections

An existing anti-stroke drug is an effective treatment for middle-ear infections, showing the ability to suppress mucus overproduction, improve bacterial clearance and reduce hearing loss, according to researchers at Georgia State University and the University of Rochester. [More]
Nanoparticle-based therapy effective in treating mice with multiple myeloma

Nanoparticle-based therapy effective in treating mice with multiple myeloma

Researchers have designed a nanoparticle-based therapy that is effective in treating mice with multiple myeloma, a cancer of immune cells in the bone marrow. [More]
Discovery Lab enrolls first patient in phase 2a clinical trial of AEROSURF

Discovery Lab enrolls first patient in phase 2a clinical trial of AEROSURF

Discovery Laboratories, Inc., a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today reported that the first patient has been enrolled in the next phase of its phase 2a clinical evaluation of AEROSURF, which is designed to evaluate the safety and tolerability of higher and repeat doses of aerosolized KL4 surfactant administered to premature infants 29 to 34 weeks gestational age (GA) who are receiving nasal continuous positive airway pressure (nCPAP) for respiratory distress syndrome (RDS), compared to infants receiving nCPAP alone. [More]
DNAtrix signs agreement to utilize Alcyone's MEMS platform for direct drug delivery into glioblastoma

DNAtrix signs agreement to utilize Alcyone's MEMS platform for direct drug delivery into glioblastoma

Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions and targeted drug delivery, and DNAtrix Inc., a privately held biotechnology company and a leader in oncolytic virus therapy, have entered into an exclusive clinical collaboration. Under the agreement, DNAtrix will utilize Alcyone's MEMS Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrix's lead product for the treatment of the most aggressive form of brain cancer, glioblastoma (GBM). [More]
MIT researchers find way to develop implantable devices that can avoid scar-tissue buildup

MIT researchers find way to develop implantable devices that can avoid scar-tissue buildup

Biomedical devices that can be implanted in the body for drug delivery, tissue engineering, or sensing can help improve treatment for many diseases. However, such devices are often susceptible to attack by the immune system, which can render them useless. [More]
Research leads way for noninvasive detection of early stage liver cancer

Research leads way for noninvasive detection of early stage liver cancer

Led by Georgia State University, researchers have developed the first robust and noninvasive detection of early stage liver cancer and liver metastases, in addition to other liver diseases, such as cirrhosis and liver fibrosis. [More]
Debiotech agrees to acquire exclusive rights on iSense CGM technology for use with patch pumps

Debiotech agrees to acquire exclusive rights on iSense CGM technology for use with patch pumps

Debiotech of Switzerland and iSense CGM, Inc. of the US, announced today having entered into an Agreement under which Debiotech has the option to acquire the exclusive rights on the iSense CGM product and technology for use with patch pumps for diabetes therapy. Financial terms and conditions of the Agreement are not disclosed. [More]
Experimental cancer drug shows promise against incurable paediatric brain cancer

Experimental cancer drug shows promise against incurable paediatric brain cancer

US-Australian drug discovery company, Novogen Limited, in conjunction with Australian paediatric cancer researchers, released key pre-clinical data on experimental cancer drug-candidate, TRXE-009, confirming its potential to become an important new therapy against an incurable paediatric brain cancer called DIPG (diffuse intrinsic pontine glioma). [More]
Unique real-time drug monitoring system

Unique real-time drug monitoring system

Titan Enterprises assisted CRISI in the early days of development of the unique flow sensor used in the BD Intelliportâ„¢, a medication management system for manual intravenous (IV) bolus injections... [More]
BD reports revenues of $2.051 billion for second fiscal quarter 2015

BD reports revenues of $2.051 billion for second fiscal quarter 2015

BD (Becton, Dickinson and Company), a leading global medical technology company, today reported quarterly revenues of $2.051 billion for the second fiscal quarter ended March 31, 2015, representing a decrease of 1.0 percent from the prior-year period, or an increase of 4.9 percent on a foreign currency-neutral basis. [More]
Global haemophilia therapeutics market estimated to reach $13.43 billion in 2019

Global haemophilia therapeutics market estimated to reach $13.43 billion in 2019

Increased uptake of recombinant therapies and prophylactic use, coupled with improved diagnosis of haemophilia, is expected to drive the associated therapeutics market. Recombinant therapies are likely to command a premium price and fuel growth in developed markets, while heightened access to treatment and larger patient volumes due to more funding for critical care are anticipated to contribute to demand in emerging markets. [More]

Illinois chemists develop new technique for making tiny silicone microspheres

Technology in common household humidifiers could enable the next wave of high-tech medical imaging and targeted medicine, thanks to a new method for making tiny silicone microspheres developed by chemists at the University of Illinois. [More]
Juniper's total revenues increase 19% to $8.3 million in first quarter 2015

Juniper's total revenues increase 19% to $8.3 million in first quarter 2015

Juniper Pharmaceuticals, Inc., today announced financial results for the three-month period ended March 31, 2015. [More]
Indivior reports top-line results from RBP-7000 phase 3 trial for treatment of schizophrenia

Indivior reports top-line results from RBP-7000 phase 3 trial for treatment of schizophrenia

Indivior PLC today announced top-line results from its phase 3 clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia. In this pivotal study, both doses of RBP-7000 tested, 90 mg and 120 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in the symptoms of acute schizophrenia over an 8-week treatment period. [More]
UNC researchers use exosomes to deliver potent Parkinson's treatment directly to the brain

UNC researchers use exosomes to deliver potent Parkinson's treatment directly to the brain

Researchers at the University of North Carolina at Chapel Hill have used exosomes -- tiny bubbles of protein and fat produced naturally by cells -- to bypass the body's defenses and deliver a potent antioxidant directly to the brain to treat Parkinson's disease. [More]
Stempeutics Research granted process patent in China for novel stem-cell based drug Stempeucel

Stempeutics Research granted process patent in China for novel stem-cell based drug Stempeucel

Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced today that the State Intellectual Property Office of China granted a process patent for its novel stem-cell based drug Stempeucel. [More]
TWi signs Settlement Agreement with Takeda on patent litigation related to generic Dexilant

TWi signs Settlement Agreement with Takeda on patent litigation related to generic Dexilant

TWi Pharmaceuticals, Inc. today announced that it has entered into a Settlement Agreement with Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceuticals America, Inc. (individually and collectively, "Takeda") to settle and dismiss all outstanding patent litigation related to TWi's generic dexlansoprazole delayed release capsules for oral administration in 30 mg and 60 mg dosage strengths. [More]

New fluid gels delay release of drugs to benefit young children, others

SCIENTISTS at the University of Huddersfield are pioneering the use of a special gel that is ideal for administering medication to young children and others - including the elderly - who have difficulty swallowing pills and capsules. Unlike purely liquid medicines, the gel delays the release of the drug, so that it has maximum effect. [More]
New Cannabis and Cannabinoid Research journal to be launched in fall 2015

New Cannabis and Cannabinoid Research journal to be launched in fall 2015

Cannabis and Cannabinoid Research, a new peer-reviewed, open access journal from Mary Ann Liebert, Inc., publishers, is the only journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the biochemical mechanisms of endocannabinoids. [More]
Nuvo Research provides details of new WF10 Phase 2 clinical trial for treatment of allergic rhinitis

Nuvo Research provides details of new WF10 Phase 2 clinical trial for treatment of allergic rhinitis

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced additional details of its new Phase 2 clinical trial (the 2015 WF10 Trial) to assess WF10 for the treatment of allergic rhinitis. [More]
Advertisement
Advertisement